MBRX.O (MBRX.O) News
Track canonical SquawkNews coverage tagged to MBRX.O, MBRX.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Moleculin says Annamycin preclinical data show CD8+ T cell — mediated activity in pancreatic cancer models
Moleculin Biotech disclosed new preclinical pancreatic cancer data on Annamycin, presented at the AACR Conference on Pancreatic Cancer. Findings suggest the drug’s antitumor effect is partly driven by CD8+ T cells, indic
NEWS | Sep 25, 2026, 05:06 PM UTC
L
Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold
Moleculin Biotech received a Nasdaq staff determination letter on Sept. 15, 2026, flagging noncompliance with the $1 minimum bid rule. Shares closed below $1 for 30 straight business days from July 31, 2026 through Sept.
REGULATION | Sep 18, 2026, 09:02 PM UTC